Research Hub
Curated, peer-reviewed research to help patients, caregivers, and clinicians stay informed on the latest advances in oncology.
A Phase III multicenter trial evaluating the combination of nivolumab and ipilimumab in patients with mismatch repair-deficient metastatic colorectal cancer is currently recruiting. Preliminary…
A landmark study demonstrates that pembrolizumab combined with standard chemotherapy significantly extends progression-free survival in patients with mismatch repair-deficient colorectal cancer.
A Phase III multicenter trial evaluating the combination of nivolumab and ipilimumab in patients with mismatch repair-deficient metastatic colorectal cancer is currently recruiting. Preliminary…
Updated guidelines recommend colorectal cancer screening starting at age 45 for average-risk adults.
A landmark study demonstrates that pembrolizumab combined with standard chemotherapy significantly extends progression-free survival in patients with mismatch repair-deficient colorectal cancer.